相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi et al.
GUT (2023)
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A. Martin-Serrano et al.
GUT (2023)
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells
Jerome Fortin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)
Effi cacy of a Small-Molecule Inhibitor of Kras G12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp et al.
CANCER DISCOVERY (2023)
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)
Tatsuya Ioka et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2023)
Rational development of combination therapies for biliary tract cancers
James J. Harding et al.
JOURNAL OF HEPATOLOGY (2023)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley et al.
LANCET (2023)
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Ruiwen Ruan et al.
MOLECULAR CANCER (2023)
Cholangiocarcinoma - novel biological insights and therapeutic strategies
Sumera I. Ilyas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma
Naoshi Nishida et al.
CANCERS (2023)
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma
Chunbin Zhu et al.
JHEP Reports (2023)
Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment
Mirko Minini et al.
CURRENT ONCOLOGY (2023)
Inhibition of FGFR Reactivates IFNg Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
Yusuke Adachi et al.
CANCER RESEARCH (2022)
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity
Tu-Xiong Huang et al.
GUT (2022)
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Meng-Ju Wu et al.
CANCER DISCOVERY (2022)
GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity
Luis Ruffolo et al.
GUT (2022)
HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability
Masahito Kawazu et al.
GASTROENTEROLOGY (2022)
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam et al.
CANCER DISCOVERY (2022)
Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma
Guohe Song et al.
NATURE COMMUNICATIONS (2022)
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
Do-Youn Oh et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung et al.
FRONTIERS IN MEDICINE (2022)
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M. Maio et al.
ANNALS OF ONCOLOGY (2022)
Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma
Youpei Lin et al.
CANCER DISCOVERY (2022)
Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis
Bridget P. Keenan et al.
CELL REPORTS (2022)
Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis
Xuanwen Bao et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Kabir Mody et al.
JCO PRECISION ONCOLOGY (2022)
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma
Laurence P. Diggs et al.
JOURNAL OF HEPATOLOGY (2021)
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle et al.
Lancet Gastroenterology & Hepatology (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma
Naoshi Nishida
CANCERS (2021)
Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice
Simon Wabitsch et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2021)
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
Masahiro Morita et al.
LIVER CANCER (2021)
Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Shipra Das et al.
CANCER RESEARCH (2020)
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Sylvie Job et al.
HEPATOLOGY (2020)
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal et al.
JOURNAL OF HEPATOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma
Min Zhang et al.
JOURNAL OF HEPATOLOGY (2020)
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
Emilien Loeuillard et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Ela Elyada et al.
CANCER DISCOVERY (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Macrophage targeting: opening new possibilities for cancer immunotherapy
Luca Cassetta et al.
IMMUNOLOGY (2018)
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Christopher P. Wardell et al.
JOURNAL OF HEPATOLOGY (2018)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
Andreas R. de Biasi et al.
CLINICAL CANCER RESEARCH (2014)
Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
Veronika Vlkova et al.
ONCOTARGET (2014)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Jesper B. Andersen et al.
GASTROENTEROLOGY (2012)
The role of PARP in DNA repair and its therapeutic exploitation
M. Javle et al.
BRITISH JOURNAL OF CANCER (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)